Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators.

N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.

2.

Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.

Kumar A, Hozo I, Wheatley K, Djulbegovic B.

Am J Hematol. 2011 Jan;86(1):18-24. doi: 10.1002/ajh.21904. Review.

3.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

4.

Bortezomib in the front-line treatment of multiple myeloma.

Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Review.

PMID:
18588451
5.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

6.

Advances in therapy of multiple myeloma.

Bladé J, Rosiñol L.

Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984. Review.

PMID:
18841053
7.

Management of older patients with multiple myeloma.

Gay F, Palumbo A.

Blood Rev. 2011 Mar;25(2):65-73. doi: 10.1016/j.blre.2010.10.003. Epub 2011 Feb 4. Review.

PMID:
21295387
8.

Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Kristinsson SY, Landgren O, Rajkumar VS.

Cancer J. 2009 Nov-Dec;15(6):473-8. doi: 10.1097/PPO.0b013e3181c60f08. Review.

9.

Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

Palumbo A, Mateos MV, Bringhen S, San Miguel JF.

Blood Rev. 2011 Jul;25(4):181-91. doi: 10.1016/j.blre.2011.03.005. Epub 2011 Apr 16. Review.

PMID:
21497966
10.

[Therapy of multiple myeloma: indications and options].

Peest D, Ganser A.

Internist (Berl). 2007 Dec;48(12):1343-8. Review. German.

PMID:
17960351
11.

Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.

Moreau P, Hulin C, Facon T.

Hematol Oncol Clin North Am. 2014 Oct;28(5):829-38. doi: 10.1016/j.hoc.2014.06.002. Epub 2014 Jul 15. Review.

PMID:
25212885
12.

Bortezomib for previously untreated multiple myeloma.

de la Rubia J, Roig M.

Expert Rev Hematol. 2011 Aug;4(4):381-98. doi: 10.1586/ehm.11.38. Review.

PMID:
21801129
13.

Part II: role of maintenance therapy in transplant-ineligible patients.

Palumbo A, Mina R.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):43-9. Review.

PMID:
23307980
14.

Treatment of newly diagnosed myeloma in patients not eligible for transplantation.

Mateos MV, San-Miguel J.

Curr Hematol Malig Rep. 2011 Jun;6(2):113-9. doi: 10.1007/s11899-011-0080-3. Review.

PMID:
21347656
15.

Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

Rajkumar SV.

Hematology Am Soc Hematol Educ Program. 2012;2012:354-61. doi: 10.1182/asheducation-2012.1.354. Review.

PMID:
23233604
16.

[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].

Tsurumi H.

Rinsho Ketsueki. 2014 Oct;55(10):2027-35. Review. Japanese. No abstract available.

PMID:
25297768
17.

Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.

Sekiguchi Y, Shirane S, Imai H, Sugimoto K, Wakabayashi M, Sawada T, Chigira N, Ichikawa K, Komatsu N, Noguchi M.

Intern Med. 2012;51(11):1393-8. Epub 2012 Jun 1. Review.

18.

How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.

Mateos MV.

Leuk Res. 2012 Nov;36 Suppl 1:S35-43. doi: 10.1016/S0145-2126(12)70007-3. Review.

PMID:
23176723
19.

[Multiple myeloma].

Iida S.

Rinsho Ketsueki. 2012 Feb;53(2):155-63. Review. Japanese. No abstract available.

PMID:
22450574
20.

Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma.

Oshikawa G, Kojima A, Doki N, Kobayashi T, Kakihana K, Tsuda H, Endo I, Kamata N, Ohashi K, Sakamaki H.

Intern Med. 2013;52(1):111-4. Epub 2013 Jan 1. Review.

Supplemental Content

Support Center